AR029619A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR029619A1
AR029619A1 ARP000100821A ARP000100821A AR029619A1 AR 029619 A1 AR029619 A1 AR 029619A1 AR P000100821 A ARP000100821 A AR P000100821A AR P000100821 A ARP000100821 A AR P000100821A AR 029619 A1 AR029619 A1 AR 029619A1
Authority
AR
Argentina
Prior art keywords
medicine
refers
ige
new
regions
Prior art date
Application number
ARP000100821A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of AR029619A1 publication Critical patent/AR029619A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP000100821A 1999-02-25 2000-02-25 Vacuna AR029619A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine

Publications (1)

Publication Number Publication Date
AR029619A1 true AR029619A1 (es) 2003-07-10

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100821A AR029619A1 (es) 1999-02-25 2000-02-25 Vacuna

Country Status (18)

Country Link
EP (1) EP1155038A1 (zh)
JP (1) JP2002537403A (zh)
KR (1) KR20020007314A (zh)
CN (1) CN1520423A (zh)
AR (1) AR029619A1 (zh)
AU (1) AU3281100A (zh)
CA (1) CA2363641A1 (zh)
CO (1) CO5231139A1 (zh)
CZ (1) CZ20013081A3 (zh)
HK (1) HK1043134A1 (zh)
HU (1) HUP0105490A3 (zh)
IL (1) IL145025A0 (zh)
MX (1) MXPA01008612A (zh)
NO (1) NO20014131L (zh)
NZ (1) NZ513680A (zh)
PL (1) PL350992A1 (zh)
TR (1) TR200102493T2 (zh)
WO (1) WO2000050461A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2206701A (en) * 1999-12-21 2001-07-03 Acambis Research Limited A reversible linkage technology for controlled conjugation
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
BR0312935A (pt) 2002-07-17 2005-06-21 Cytos Biotechnology Ag Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
NZ537688A (en) 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
NZ542323A (en) 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
CA2552999A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
DK2032592T3 (da) 2006-06-12 2013-09-02 Cytos Biotechnology Ag Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
CN111936856A (zh) * 2018-04-06 2020-11-13 Sls生物有限公司 新型免疫球蛋白e的表位、与其结合的抗体及包括所述抗体的用于分析试料中免疫球蛋白e的试剂盒
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (ja) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有するペプチド
DE122006000006I2 (de) * 1991-08-14 2011-06-16 Genentech Inc Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
RU2193413C2 (ru) * 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
EP1155038A1 (en) 2001-11-21
AU3281100A (en) 2000-09-14
TR200102493T2 (tr) 2002-02-21
NO20014131D0 (no) 2001-08-24
HK1043134A1 (zh) 2002-09-06
WO2000050461A1 (en) 2000-08-31
CN1520423A (zh) 2004-08-11
HUP0105490A2 (hu) 2002-04-29
NO20014131L (no) 2001-10-02
CO5231139A1 (es) 2002-12-27
NZ513680A (en) 2001-09-28
CA2363641A1 (en) 2000-08-31
IL145025A0 (en) 2002-06-30
KR20020007314A (ko) 2002-01-26
HUP0105490A3 (en) 2002-05-28
JP2002537403A (ja) 2002-11-05
CZ20013081A3 (cs) 2002-02-13
MXPA01008612A (es) 2003-06-24
PL350992A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
AR029619A1 (es) Vacuna
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
Harrison et al. Research strategies to improve snakebite treatment: Challenges and progress
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
AR066987A1 (es) Anticuerpo monoclonal contra proteina beta-amiloide
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
ATE414534T1 (de) Immunotherapeutische methoden und systeme
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
EA202191244A1 (ru) Новые цитостатические конъюгаты с лигандами интегрина
DK1684869T3 (da) Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
ES2376564B1 (es) Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
Sibaud et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
EA201500506A1 (ru) КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a
BR112023002301A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
RU2011130522A (ru) Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
Lee et al. Bee venom-associated Th1/Th2 immunoglobulin class switching results in immune tolerance of NZB/W F1 murine lupus nephritis
AR029336A1 (es) Peptidos utiles para preparar medicamentos para el tratamiento, prevencion o mejoramiento de estados alergicos, inmunogenos,epitopos y mimotopos, vacunas, ligandos, composiciones farmaceuticas; uso de los peptidos ,de los ligandos en la preparacion de medicamentos; proceso para preparar vacunas y pr
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye

Legal Events

Date Code Title Description
FA Abandonment or withdrawal